Transgenic Mice Overexpressing the 5-Hydroxytryptamine Transporter Gene in Smooth Muscle Develop Pulmonary Hypertension

One intrinsic abnormality of pulmonary artery smooth muscle cells (PA-SMCs) in human idiopathic pulmonary hypertension (iPH) is an exaggerated proliferative response to internalized serotonin (5-HT) caused by increased expression of the 5-HT transporter (5-HTT). To investigate whether 5-HTT overexpression in PA-SMCs is sufficient to produce PH, we generated transgenic mice overexpressing 5-HTT under the control of the SM22 promoter. Studies in SM22-LacZ+ mice showed that the transgene was expressed predominantly in SMCs of pulmonary and systemic vessels. Compared with wild-type mice, SM22–5-HTT+ mice exhibited a 3- to 4-fold increase in lung 5-HTT mRNA and protein, together with increased lung 5-HT uptake activity, but no changes in platelet 5-HTT activity or blood 5-HT levels. At 8 weeks of age, SM22–5-HTT+ mice exhibited PH, with marked increases in right ventricular systolic pressure (RVSP), right ventricle/left ventricle+septum ratio, and muscularization of distal pulmonary vessels, but no changes in systemic arterial pressure. PH worsened with age. Except a marked decrease in Kv channels, no changes in the lung expression of mediators of pulmonary vascular remodeling were observed in SM22–5-HTT+ mice. Compared with wild-type mice, SM22–5-HTT+ mice showed depressed hypoxic pulmonary vasoconstriction contrasting with greater severity of hypoxia- or monocrotaline-induced PH. These results show that increased 5-HTT expression in PA-SMCs, to a level close to that found in human iPH, lead to PH in mice. They further support a central role for 5-HTT in the pathogenesis of PH, making 5-HTT a potential therapeutic target.

[1]  Yingling Liu,et al.  Serotonin-induced growth of pulmonary artery smooth muscle requires activation of phosphatidylinositol 3-kinase/serine-threonine protein kinase B/mammalian target of rapamycin/p70 ribosomal S6 kinase 1. , 2006, American journal of respiratory cell and molecular biology.

[2]  J. Loscalzo,et al.  Increased Susceptibility to Pulmonary Hypertension in Heterozygous BMPR2-Mutant Mice , 2005, Circulation.

[3]  S. Adnot.  Lessons learned from cancer may help in the treatment of pulmonary hypertension. , 2005, The Journal of clinical investigation.

[4]  M. Hamon,et al.  Serotonin Transporter Inhibition Prevents and Reverses Monocrotaline-Induced Pulmonary Hypertension in Rats , 2005, Circulation.

[5]  M. Humbert,et al.  Cellular and molecular pathobiology of pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[6]  M. Humbert,et al.  Serotonin-Induced Smooth Muscle Hyperplasia in Various Forms of Human Pulmonary Hypertension , 2004, Circulation research.

[7]  A. Harmar,et al.  Overexpression of the 5-Hydroxytryptamine Transporter Gene: Effect on Pulmonary Hemodynamics and Hypoxia-Induced Pulmonary Hypertension , 2004, Circulation.

[8]  E. Fadel,et al.  Polymorphism of the Serotonin Transporter Gene and Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease , 2003, Circulation.

[9]  P. Thistlethwaite,et al.  Signaling molecules in nonfamilial pulmonary hypertension. , 2003, The New England journal of medicine.

[10]  M. Humbert,et al.  Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. , 2001, The Journal of clinical investigation.

[11]  Ying Yu,et al.  c-Jun Decreases Voltage-Gated K+ Channel Activity in Pulmonary Artery Smooth Muscle Cells , 2001, Circulation.

[12]  M. Hamon,et al.  Dexfenfluramine-associated changes in 5-hydroxytryptamine transporter expression and development of hypoxic pulmonary hypertension in rats. , 2001, The Journal of pharmacology and experimental therapeutics.

[13]  N. Voelkel,et al.  Gene Expression Patterns in the Lungs of Patients With Primary Pulmonary Hypertension: A Gene Microarray Analysis , 2001, Circulation research.

[14]  S. Hodge,et al.  Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. , 2000, American journal of human genetics.

[15]  R. Trembath,et al.  Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension , 2000, Nature Genetics.

[16]  K. Lesch,et al.  Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. , 2000, The Journal of clinical investigation.

[17]  D. Badesch,et al.  Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. , 1999, American journal of respiratory and critical care medicine.

[18]  M. Martres,et al.  Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cells. Relationship with the mitogenic action of serotonin. , 1999, Circulation research.

[19]  N. Chandel,et al.  Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[20]  S. Archer,et al.  Molecular identification of the role of voltage-gated K+ channels, Kv1.5 and Kv2.1, in hypoxic pulmonary vasoconstriction and control of resting membrane potential in rat pulmonary artery myocytes. , 1998, The Journal of clinical investigation.

[21]  M. Juhaszova,et al.  Attenuated K+ channel gene transcription in primary pulmonary hypertension , 1998, The Lancet.

[22]  J. Small,et al.  The SM 22 promoter directs tissue-specific expression in arterial but not in venous or visceral smooth muscle cells in transgenic mice. , 1996, Development.

[23]  D. Stewart,et al.  Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. , 1993, The New England journal of medicine.

[24]  B. Groves,et al.  An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. , 1992, The New England journal of medicine.

[25]  S. Archer,et al.  Direct role for potassium channel inhibition in hypoxic pulmonary vasoconstriction. , 1992, The American journal of physiology.

[26]  B. Fanburg,et al.  Dual effect of serotonin on growth of bovine pulmonary artery smooth muscle cells in culture. , 1991, Circulation research.

[27]  H. Acker,et al.  Involvement of an NAD(P)H oxidase as a pO2 sensor protein in the rat carotid body. , 1990, The Biochemical journal.

[28]  M. Hamon,et al.  Alterations of central serotonin and dopamine turnover in rats treated with ipsapirone and other 5-hydroxytryptamine1A agonists with potential anxiolytic properties. , 1988, The Journal of pharmacology and experimental therapeutics.

[29]  C. Wagenvoort,et al.  Primary Pulmonary Hypertension: A Pathologic Study of the Lung Vessels in 156 Clinically Diagnosed Cases , 1970 .

[30]  Sujoy Khan.  Acute oxygen-sensing mechanisms. , 2006, The New England journal of medicine.